Healthcare Global Enterprises Ltd Q2 FY26 Results & Concall Highlights: Revenue ₹4,000 Cr
Published 8 Aug 2026 | Healthcare Services | Market Cap: ₹10.7K Cr
Overall revenue growth expected to outpace industry, sustaining over 15% per annum. Revenue growth expected at 15%+ CAGR over medium to long term, outpacing industry growth.
From Healthcare Global Enterprises Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹726
Market Cap
₹10.7K Cr
P/E Ratio
221.3
How does Healthcare Global Enterprises Ltd rank in Healthcare Services?
Compare Healthcare Global Enterprises Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Healthcare Global Enterprises Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹652 Cr, net profit ₹4 Cr.
Full financials →📊 Revenue & Sales Performance
- →Overall revenue growth expected to outpace industry, sustaining over 15% per annum.
- →Average realization improvement targeted at 4% to 5% annually.
- →Inpatient volume growth anticipated at 9% to 10% in near to midterm.
- →Incremental revenue growth split: 70%-75% from existing centres, 10%-15% from brownfield expansion, and 8%-10% from greenfield projects.
- →Existing network has significant growth potential through capacity expansion, addition of clinical teams, specialty mix enhancement, and technology upgrades.
- →Medium-term goal to realize Rs.4,000 crore revenue potential over 4-5 years from current Rs.2,200 crore at existing price points and optimized utilization.
- →Network growth driven by deepening clinical presence, expanding clinical domains, improving payor mix, strengthening brand, and scaling international business.
- →New markets and acquisitions to add approximately 1,000 beds and 10 additional LINACs.
📈 Profitability & Margins
- →Revenue growth expected at 15%+ CAGR over medium to long term, outpacing industry growth.
- →EBITDA expected to grow faster than historical CAGR of 18%, supported by operational efficiencies, improved payor mix, and network optimization.
- →Mature centers delivering EBITDA margins of 25% pre-corporate cost and ROCE around 27%; company-wide EBITDA margin expected to improve to 21%-22% in near term and higher in the long term.
- →Incremental revenue largely from existing centers (70%-75%) with expansion via brownfield and greenfield projects adding about 1,000 beds and 10 LINACs.
- →ROCE expected to be sustainably 20%+ over next five years as more centers mature and profitability improves.
- →Capex of Rs.600-700 crore planned over 2-3 years, funded mainly through internal accruals to maintain net debt/EBITDA ratio between 2-2.5x.
🏗️ Capital Expenditure Plans
- →Next 2-3 years planned capex: Rs. 600-700 crore
- → - Rs. 300 crore dedicated to maintenance capex
- → - Remaining for upgrading infrastructure, increasing existing capacity, and brownfield expansion
- →Brownfield expansion to add around 700 beds in markets like Ahmedabad, Vizag, Baroda, Cuttack
- →Greenfield expansion planned in 10-12 new cities (e.g., Pune, Surat, Varanasi, Kanpur), adding 200-400 beds
- →Greenfield projects largely funded through internal accruals, maintaining net debt to EBITDA ratio of 2-2.5x
- →Each new centre's capex approximately Rs. 100 crore depending on market specifics
- →Focus on cautious, disciplined capital allocation with emphasis on improving existing network efficiency and expanding through targeted market entry
💰 Fundraising & Capital Structure
- →The company has conserved capital over the last five years, reducing net debt to EBITDA ratio from 6.2x in FY2020 to about 2.3x in FY2025, showing focus on deleveraging.
- →Current net debt to EBITDA ratio is comfortable at around 2.5x, with prudent leverage management.
- →Capex of Rs.600-700 crore planned over the next 2-3 years; funding primarily to come from internal accruals and available borrowing headroom.
- →The company is evaluating its equity and debt ratio and will take appropriate calls on raising equity or debt at the right time.
- →For greenfield expansion, internal accruals will be the primary source of capital.
- →No specific or immediate fundraising announced; future equity or debt raises will be considered as per strategic need.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Healthcare Global Enterprises Ltd Q2 FY26 results?
Overall revenue growth expected to outpace industry, sustaining over 15% per annum. Revenue growth expected at 15%+ CAGR over medium to long term, outpacing industry growth.
What is Healthcare Global Enterprises Ltd share price analysis?
Healthcare Global Enterprises Ltd currently shows a neutral. The stock trades at a P/E of 221.3 with a market cap of ₹10,665 Cr. Investors should review the full earnings analysis for detailed insights.
Is Healthcare Global Enterprises Ltd planning capital expenditure?
Next 2-3 years planned capex: Rs.
Keep Healthcare Global Enterprises Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.